CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, announces a nationwide program of free screening days to be held in collaboration with its Centers of Excellence, other orthotics and prosthetics practices and its rehabilitation therapy partners.
Myomo and its partners will offer potential users a convenient chance to be evaluated by clinical specialists and to examine a MyoPro powered brace for themselves to determine if MyoPro might help them overcome upper-limb paralysis caused by stroke, brachial plexus injury or other neuromuscular disease or injury.
During May, free open screening clinics are planned for Boston; Hartford, Conn.; New York City; Livonia, Madison Heights, Ann Arbor, Grand Rapids, Grand Blanc and Detroit, Mich.; Chicago; Milwaukee; Cincinnati, Cleveland and Columbus, Ohio; Salt Lake City; and San Francisco. Screenings at additional locations are planned for June.
Exact dates and locations, more information and no-cost, no obligation registration may be found at www.myomo.com/screening.
This nationwide rollout of the screening program follows a successful pilot screening program at Geauga Rehabilitation Engineering (GRE), a Myomo Center of Excellence partner, during the first quarter of 2018 in Cleveland, Columbus, Cincinnati and Detroit.
“Many individuals with a paralyzed arm and hand after a stroke or injury are told they’ll never use that limb again for the rest of their lives,” said Cliff Conneighton, Myomo’s Chief Marketing Officer. “With our MyoPro powered arm brace, many are able to regain movement and restore functional ability so they can return to work, feed themselves, and perform daily living tasks. We are launching this screening campaign to educate and assist more individuals, families, physicians and therapists about the benefit of the MyoPro myoelectric orthosis.”
Most commercial healthcare plans, multiple Medicaid plans, workers’ compensation and Medicare Advantage plans have covered the device based on medical necessity and the potential to reduce healthcare costs. Eligible veterans may receive a MyoPro through their local VA Medical Center.
About Myomo
Myomo, Inc. is a commercial stage medical
robotics company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb orthosis
designed to support the arm and restore function to the weakened or
paralyzed arms of patients suffering from CVA stroke, brachial plexus
injury, traumatic brain or spinal cord injury, ALS or other
neuromuscular disease or injury. It is currently the only marketed
device that, sensing a patient’s own EMG signals through non-invasive
sensors on the arm, can restore an individual’s ability to perform
activities of daily living, including feeding themselves, carrying
objects and doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered in
Cambridge, Massachusetts, with sales and clinical professionals across
the U.S. For more information, please visit www.myomo.com.
Forward Looking Statements
This press release contains
forward-looking statements regarding the Company's future business
expectations, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are only predictions and may differ materially from actual
results due to a variety of factors. Our actual results could differ
materially from those anticipated in these forward looking statements
for many reasons, including, without limitation, risks related to
regulatory approval and market acceptance of our products, and the other
risk factors contained in our filings made with the Securities and
Exchange Commission. More information about factors that potentially
could affect Myomo's financial results is included in Myomo's filings
with the Securities and Exchange Commission. The Company cautions
readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date made. The Company disclaims
any obligation subsequently to revise any forward-looking statements to
reflect events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.